Catheter Precision, Inc. (VTAK): M&A transaction — Catheter Precision subsidiary acquires Cardionomic's heart failure assets for 1M shares and $1.5M note

Catheter Precision, Inc.

Cardionomix purchased CNPS System patents/trademarks for heart failure; closed May 5, 2025.
Consideration: 1M restricted VTAK shares and $1.5M note at 4% due May 2028.
Cardionomix minority stakes: CEO Jenkins (5%), FatBoy Capital (7%), others; requires development financing.
Company seeking additional financing including ATM offering; warns of dilution.
Assets acquired 'AS IS'; Cardionomix has no other significant assets.

item 1.01 item 2.03 item 2.01 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Catheter Precision, Inc. incurred loan of $1.5 million with Cardionomic (assignment for the benefit of creditors), LLC at 4% per annum maturing May 5, 2028.

Instrument: loan
Principal: $1.5 million
Counterparty: Cardionomic (assignment for the benefit of creditors), LLC
Rate: 4% per annum
Maturity: May 5, 2028
Event: incurrence

Exact text from the filing

the issuance by Cardionomix of a promissory note (the "Note") in the amount of $1.5 million, with simple interest accruing at 4% per annum on the principal thereof and no interest or principal payable until the maturity date of the Note, which will be May 5, 2028

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Catheter Precision, Inc. completed an acquisition involving Cardionomic (assignment for the benefit of creditors), LLC for 1,000,000 restricted shares of the Company's common stock and a promissory note in the amount of $1.5 million (closed 2025-05-05).

Action: acquisition
Counterparty: Cardionomic (assignment for the benefit of creditors), LLC
Consideration: 1,000,000 restricted shares of the Company's common stock and a promissory note in the amount of $1.5 million
Closing: 2025-05-05

Exact text from the filing

or warranties as to merchantability, fitness or use from Seller and no representations from or privity with Assignor, in exchange for the issuance by the Company of 1,000,000 restricted shares of the Company's common stock, $0.0001 par value per share (the “Share Consideration”) and the issuance by Cardionomix of a promissory note (the "Note") in the

View on SEC.gov

101 debt financings filed in the last 30 days. Browse all debt financings →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-015488

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.